Minneapolis, Minn., July 19, 2016 – Driven to improve patient care and reduce overall healthcare costs, pharmacogenomics company OneOme announces the global availability of its RightMed test.
The RightMed test is a cost-effective, comprehensive pharmacogenomic analysis of 22 genes provided as a part of routine clinical care. The test helps healthcare providers easily make timely, evidenced-based, personalized prescription treatment decisions across more than 340 medications.
“As the field of genomics rapidly evolves, we’re able to learn more about how our unique genome influences our health, specifically how we metabolize prescription drugs,” said Megan Adelman, PharmD with OneOme. “We know that about half of the four billion prescriptions issued each year do not work as intended, so we are excited to introduce this product into routine clinical care.”
The test, which costs $249, is ordered by providers through a HIPAA-compliant portal at www.oneome.com, where results will be made available and retained. Results are tested at OneOme’s brand new CLIA-registered clinical laboratory in Minneapolis, Minnesota, which has been successfully running tests since early summer. OneOme’s RightMed interpretation is also used by Mayo Clinic Center for Individualized Medicine (CIM).
While anyone can take the simple cheek-swab test, it is most beneficial for patients with adverse drug reactions, cardiovascular drug prescriptions, medications that are not working, multiple prescription medications, and unwelcomed side effects from current medications.
Available worldwide, the RightMed test is provided in Canada through OneOme’s partnership with Medcan, Canada’s largest executive health clinic and a global leader in assessing clients’ overall well-being through its Annual Health Assessment.
“For more than 25 years, Medcan’s team of physicians and specialists have provided diagnostic assessments to help clients successfully reach improved health outcomes,” said Jill Davies, MSc, CCGC, Director, Genetics and Business Development. “With innovation at the core of our genetics specialty, we are thrilled to incorporate OneOme’s comprehensive RightMed test into our assessments and to be able to provide in-depth and actionable consultation to our clients.”
In addition, the RightMed test is available in Puerto Rico, Cuba, and Dominican Republic through OneOme’s partnership with High Profile Laboratory in Guaynabo, Puerto Rico. High Profiles Laboratory is an established, specialized provider of clinical and microbiological tests and a partner of Salus, a healthcare provider and a member of the Mayo Clinic Care Network.
“It’s our mission to build the most comprehensive, affordable, and personalized analysis in pharmacogenomics, both for providers and their patients, but also to advance the Precision Medicine Initiative, which aims to provide better insights into the biological, environmental, and behavioral influences on diseases to inform treatment and prevention,” said Paul Owen, CEO of OneOme. “The comprehensiveness and affordability of the RightMed test will accelerate this initiative.”
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.